<!DOCTYPE html><html lang="en" class="dark"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/e4af272ccee01ff0-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="stylesheet" href="/_next/static/css/8d323862949ffad9.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-d2cf98d9cef4ff37.js"/><script src="/_next/static/chunks/ceb5afef-fd730bca4742d10d.js" async=""></script><script src="/_next/static/chunks/156-5c70558397be49ef.js" async=""></script><script src="/_next/static/chunks/main-app-f896963268641fe0.js" async=""></script><script src="/_next/static/chunks/863-822c2cde35e02348.js" async=""></script><script src="/_next/static/chunks/app/layout-fb78cfc571d4c3d6.js" async=""></script><title>Unloxcyt Market Survey - Interactive Presentation</title><meta name="description" content="Comprehensive market analysis of Cosibelimab-ipdl for advanced cSCC"/><meta name="next-size-adjust"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule=""></script></head><body class="__className_f367f3 h-1080px w-1920px"><!--$!--><template data-dgst="BAILOUT_TO_CLIENT_SIDE_RENDERING"></template><!--/$--><div class="relative overflow-hidden w-[1920px] h-[1080px] bg-gradient-to-br from-slate-900 to-slate-700 text-white"><div class="flex flex-col w-full h-full"><div class="flex-none bg-slate-800/90 p-6 flex items-center gap-4"><svg xmlns="http://www.w3.org/2000/svg" width="48" height="48" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-award text-orange-400"><path d="m15.477 12.89 1.515 8.526a.5.5 0 0 1-.81.47l-3.58-2.687a1 1 0 0 0-1.197 0l-3.586 2.686a.5.5 0 0 1-.81-.469l1.514-8.526"></path><circle cx="12" cy="8" r="6"></circle></svg><h1 class="text-6xl font-bold text-white">Investment Thesis &amp; Conclusion</h1></div><div class="flex-1 min-h-0 grid grid-cols-[3fr_2fr] gap-6 p-8"><div class="flex flex-col gap-4"><h2 class="text-4xl font-bold text-white">Investment Thesis</h2><div class="bg-slate-800/90 p-4 rounded-lg border-l-4 border-blue-400"><p class="text-2xl bg-gradient-to-r from-blue-400 to-purple-400 bg-clip-text text-transparent font-bold">Unloxcyt offers a compelling opportunity in the cSCC market with a first-in-class mechanism, backed by Sun Pharma&#x27;s global infrastructure.</p></div><h3 class="text-4xl font-bold text-white mt-2">Why Unloxcyt Succeeds</h3><div class="space-y-4"><div class="flex items-start gap-4 bg-slate-800/90 p-3 rounded-lg"><svg xmlns="http://www.w3.org/2000/svg" width="28" height="28" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-target text-blue-400 mt-1 flex-shrink-0"><circle cx="12" cy="12" r="10"></circle><circle cx="12" cy="12" r="6"></circle><circle cx="12" cy="12" r="2"></circle></svg><div><h4 class="text-2xl font-bold text-white">Market Validation</h4><p class="text-xl text-gray-300">FDA approved; $1B+ U.S. market with strong annual growth.</p></div></div><div class="flex items-start gap-4 bg-slate-800/90 p-3 rounded-lg"><svg xmlns="http://www.w3.org/2000/svg" width="28" height="28" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-zap text-purple-400 mt-1 flex-shrink-0"><path d="M4 14a1 1 0 0 1-.78-1.63l9.9-10.2a.5.5 0 0 1 .86.46l-1.92 6.02A1 1 0 0 0 13 10h7a1 1 0 0 1 .78 1.63l-9.9 10.2a.5.5 0 0 1-.86-.46l1.92-6.02A1 1 0 0 0 11 14z"></path></svg><div><h4 class="text-2xl font-bold text-white">Differentiation Advantage</h4><p class="text-xl text-gray-300">First-and-only PD-L1 inhibitor for cSCC with a unique ADCC mechanism.</p></div></div><div class="flex items-start gap-4 bg-slate-800/90 p-3 rounded-lg"><svg xmlns="http://www.w3.org/2000/svg" width="28" height="28" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-trending-up text-green-400 mt-1 flex-shrink-0"><polyline points="22 7 13.5 15.5 8.5 10.5 2 17"></polyline><polyline points="16 7 22 7 22 13"></polyline></svg><div><h4 class="text-2xl font-bold text-white">Revenue Potential</h4><p class="text-xl text-gray-300">Peak sales projection of $1.2-1.4B with 30-35% market share capture.</p></div></div><div class="flex items-start gap-4 bg-slate-800/90 p-3 rounded-lg"><svg xmlns="http://www.w3.org/2000/svg" width="28" height="28" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-globe text-blue-400 mt-1 flex-shrink-0"><circle cx="12" cy="12" r="10"></circle><path d="M12 2a14.5 14.5 0 0 0 0 20 14.5 14.5 0 0 0 0-20"></path><path d="M2 12h20"></path></svg><div><h4 class="text-2xl font-bold text-white">Global Infrastructure</h4><p class="text-xl text-gray-300">Sun Pharma provides commercial capabilities and global expansion pathways.</p></div></div></div></div><div class="flex flex-col gap-4"><div class="bg-slate-800/90 p-4 rounded-lg"><h3 class="text-3xl font-bold text-orange-400 mb-3">Valuation Snapshot</h3><div class="space-y-2"><div class="flex justify-between items-center"><p class="text-xl text-gray-300">Acquisition Value</p><p class="text-2xl font-bold text-green-400">$416M</p></div><div class="flex justify-between items-center"><p class="text-xl text-gray-300">Peak Sales (Base)</p><p class="text-2xl font-bold text-green-400">$1.2-1.4B</p></div><div class="flex justify-between items-center"><p class="text-xl text-gray-300">Risk-Adjusted NPV</p><p class="text-2xl font-bold text-green-400">$3.0-5.5B</p></div><div class="flex justify-between items-center"><p class="text-xl text-gray-300">Time to Peak</p><p class="text-2xl font-bold text-green-400">4-6 years</p></div></div></div><div class="bg-slate-800/90 p-4 rounded-lg"><h3 class="text-3xl font-bold text-white mb-3">Risk-Reward Profile</h3><div class="space-y-2"><div class="flex justify-between items-center"><p class="text-xl text-gray-300">Risk Level</p><p class="text-xl font-bold text-orange-400">Moderate-High</p></div><div class="flex justify-between items-center"><p class="text-xl text-gray-300">Reward Potential</p><p class="text-xl font-bold text-green-400">Substantial</p></div><p class="text-base text-gray-400 pt-1">Key Risks: Competition, market capture execution</p><p class="text-base text-gray-400">Key Rewards: Billion-dollar revenue, global expansion</p></div></div><div class="bg-gradient-to-r from-purple-600 to-purple-500 p-4 rounded-lg flex-grow flex flex-col"><h3 class="text-3xl font-bold text-white mb-2">Strategic Imperative</h3><p class="text-xl text-white mb-3">Execute flawless commercialization to capture market share and build a foundation for global growth.</p><div class="space-y-1 mt-auto"><p class="text-base text-purple-100">• Immediate: U.S. market establishment</p><p class="text-base text-purple-100">• Near-term: European approvals</p><p class="text-base text-purple-100">• Long-term: Asia-Pacific expansion</p></div></div></div></div><div class="flex-none p-4 flex justify-between items-center bg-slate-800/50"><p class="text-base text-gray-400">For inquiries: strategic.intelligence@pharma.com</p><p class="text-lg text-gray-300 font-bold">Unloxcyt: Transforming Advanced cSCC Treatment</p><p class="text-base text-gray-400">10</p></div></div></div><script src="/_next/static/chunks/webpack-d2cf98d9cef4ff37.js" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0]);self.__next_f.push([2,null])</script><script>self.__next_f.push([1,"1:HL[\"/_next/static/media/e4af272ccee01ff0-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:HL[\"/_next/static/css/8d323862949ffad9.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"3:I[5616,[],\"\"]\n5:I[6146,[],\"\"]\n6:I[4411,[],\"\"]\n7:\"$Sreact.suspense\"\n8:I[7256,[\"863\",\"static/chunks/863-822c2cde35e02348.js\",\"185\",\"static/chunks/app/layout-fb78cfc571d4c3d6.js\"],\"KeyboardNavigation\"]\n9:I[5407,[\"863\",\"static/chunks/863-822c2cde35e02348.js\",\"185\",\"static/chunks/app/layout-fb78cfc571d4c3d6.js\"],\"SlideNavigation\"]\nb:I[7141,[],\"\"]\nc:[]\n"])</script><script>self.__next_f.push([1,"0:[\"$\",\"$L3\",null,{\"buildId\":\"DkpgZd6XOJjDaY981EGFp\",\"assetPrefix\":\"\",\"urlParts\":[\"\",\"pages\",\"10\"],\"initialTree\":[\"\",{\"children\":[\"pages\",{\"children\":[\"10\",{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],\"initialSeedData\":[\"\",{\"children\":[\"pages\",{\"children\":[\"10\",{\"children\":[\"__PAGE__\",{},[[\"$L4\",[\"$\",\"div\",null,{\"className\":\"relative overflow-hidden w-[1920px] h-[1080px] bg-gradient-to-br from-slate-900 to-slate-700 text-white\",\"children\":[\"$\",\"div\",null,{\"className\":\"flex flex-col w-full h-full\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex-none bg-slate-800/90 p-6 flex items-center gap-4\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":48,\"height\":48,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-award text-orange-400\",\"children\":[[\"$\",\"path\",\"1yiouv\",{\"d\":\"m15.477 12.89 1.515 8.526a.5.5 0 0 1-.81.47l-3.58-2.687a1 1 0 0 0-1.197 0l-3.586 2.686a.5.5 0 0 1-.81-.469l1.514-8.526\"}],[\"$\",\"circle\",\"1vp47v\",{\"cx\":\"12\",\"cy\":\"8\",\"r\":\"6\"}],\"$undefined\"]}],[\"$\",\"h1\",null,{\"className\":\"text-6xl font-bold text-white\",\"children\":\"Investment Thesis \u0026 Conclusion\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex-1 min-h-0 grid grid-cols-[3fr_2fr] gap-6 p-8\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-col gap-4\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"text-4xl font-bold text-white\",\"children\":\"Investment Thesis\"}],[\"$\",\"div\",null,{\"className\":\"bg-slate-800/90 p-4 rounded-lg border-l-4 border-blue-400\",\"children\":[\"$\",\"p\",null,{\"className\":\"text-2xl bg-gradient-to-r from-blue-400 to-purple-400 bg-clip-text text-transparent font-bold\",\"children\":\"Unloxcyt offers a compelling opportunity in the cSCC market with a first-in-class mechanism, backed by Sun Pharma's global infrastructure.\"}]}],[\"$\",\"h3\",null,{\"className\":\"text-4xl font-bold text-white mt-2\",\"children\":\"Why Unloxcyt Succeeds\"}],[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-start gap-4 bg-slate-800/90 p-3 rounded-lg\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":28,\"height\":28,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-target text-blue-400 mt-1 flex-shrink-0\",\"children\":[[\"$\",\"circle\",\"1mglay\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"10\"}],[\"$\",\"circle\",\"1vlfrh\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"6\"}],[\"$\",\"circle\",\"1c9p78\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"2\"}],\"$undefined\"]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"text-2xl font-bold text-white\",\"children\":\"Market Validation\"}],[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"FDA approved; $1B+ U.S. market with strong annual growth.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-4 bg-slate-800/90 p-3 rounded-lg\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":28,\"height\":28,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-zap text-purple-400 mt-1 flex-shrink-0\",\"children\":[[\"$\",\"path\",\"1xq2db\",{\"d\":\"M4 14a1 1 0 0 1-.78-1.63l9.9-10.2a.5.5 0 0 1 .86.46l-1.92 6.02A1 1 0 0 0 13 10h7a1 1 0 0 1 .78 1.63l-9.9 10.2a.5.5 0 0 1-.86-.46l1.92-6.02A1 1 0 0 0 11 14z\"}],\"$undefined\"]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"text-2xl font-bold text-white\",\"children\":\"Differentiation Advantage\"}],[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"First-and-only PD-L1 inhibitor for cSCC with a unique ADCC mechanism.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-4 bg-slate-800/90 p-3 rounded-lg\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":28,\"height\":28,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-trending-up text-green-400 mt-1 flex-shrink-0\",\"children\":[[\"$\",\"polyline\",\"126l90\",{\"points\":\"22 7 13.5 15.5 8.5 10.5 2 17\"}],[\"$\",\"polyline\",\"kwv8wd\",{\"points\":\"16 7 22 7 22 13\"}],\"$undefined\"]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"text-2xl font-bold text-white\",\"children\":\"Revenue Potential\"}],[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Peak sales projection of $1.2-1.4B with 30-35% market share capture.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-4 bg-slate-800/90 p-3 rounded-lg\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":28,\"height\":28,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-globe text-blue-400 mt-1 flex-shrink-0\",\"children\":[[\"$\",\"circle\",\"1mglay\",{\"cx\":\"12\",\"cy\":\"12\",\"r\":\"10\"}],[\"$\",\"path\",\"13o1zl\",{\"d\":\"M12 2a14.5 14.5 0 0 0 0 20 14.5 14.5 0 0 0 0-20\"}],[\"$\",\"path\",\"9i4pu4\",{\"d\":\"M2 12h20\"}],\"$undefined\"]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"text-2xl font-bold text-white\",\"children\":\"Global Infrastructure\"}],[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Sun Pharma provides commercial capabilities and global expansion pathways.\"}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex flex-col gap-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"bg-slate-800/90 p-4 rounded-lg\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"text-3xl font-bold text-orange-400 mb-3\",\"children\":\"Valuation Snapshot\"}],[\"$\",\"div\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex justify-between items-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Acquisition Value\"}],[\"$\",\"p\",null,{\"className\":\"text-2xl font-bold text-green-400\",\"children\":\"$$416M\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex justify-between items-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Peak Sales (Base)\"}],[\"$\",\"p\",null,{\"className\":\"text-2xl font-bold text-green-400\",\"children\":\"$$1.2-1.4B\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex justify-between items-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Risk-Adjusted NPV\"}],[\"$\",\"p\",null,{\"className\":\"text-2xl font-bold text-green-400\",\"children\":\"$$3.0-5.5B\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex justify-between items-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Time to Peak\"}],[\"$\",\"p\",null,{\"className\":\"text-2xl font-bold text-green-400\",\"children\":\"4-6 years\"}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"bg-slate-800/90 p-4 rounded-lg\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"text-3xl font-bold text-white mb-3\",\"children\":\"Risk-Reward Profile\"}],[\"$\",\"div\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex justify-between items-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Risk Level\"}],[\"$\",\"p\",null,{\"className\":\"text-xl font-bold text-orange-400\",\"children\":\"Moderate-High\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex justify-between items-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Reward Potential\"}],[\"$\",\"p\",null,{\"className\":\"text-xl font-bold text-green-400\",\"children\":\"Substantial\"}]]}],[\"$\",\"p\",null,{\"className\":\"text-base text-gray-400 pt-1\",\"children\":\"Key Risks: Competition, market capture execution\"}],[\"$\",\"p\",null,{\"className\":\"text-base text-gray-400\",\"children\":\"Key Rewards: Billion-dollar revenue, global expansion\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"bg-gradient-to-r from-purple-600 to-purple-500 p-4 rounded-lg flex-grow flex flex-col\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"text-3xl font-bold text-white mb-2\",\"children\":\"Strategic Imperative\"}],[\"$\",\"p\",null,{\"className\":\"text-xl text-white mb-3\",\"children\":\"Execute flawless commercialization to capture market share and build a foundation for global growth.\"}],[\"$\",\"div\",null,{\"className\":\"space-y-1 mt-auto\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-base text-purple-100\",\"children\":\"• Immediate: U.S. market establishment\"}],[\"$\",\"p\",null,{\"className\":\"text-base text-purple-100\",\"children\":\"• Near-term: European approvals\"}],[\"$\",\"p\",null,{\"className\":\"text-base text-purple-100\",\"children\":\"• Long-term: Asia-Pacific expansion\"}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex-none p-4 flex justify-between items-center bg-slate-800/50\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-base text-gray-400\",\"children\":\"For inquiries: strategic.intelligence@pharma.com\"}],[\"$\",\"p\",null,{\"className\":\"text-lg text-gray-300 font-bold\",\"children\":\"Unloxcyt: Transforming Advanced cSCC Treatment\"}],[\"$\",\"p\",null,{\"className\":\"text-base text-gray-400\",\"children\":\"10\"}]]}]]}]}],null],null],null]},[null,[\"$\",\"$L5\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"pages\",\"children\",\"10\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L6\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\"}]],null]},[null,[\"$\",\"$L5\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"pages\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L6\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\"}]],null]},[[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/8d323862949ffad9.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]],[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"dark\",\"children\":[\"$\",\"body\",null,{\"className\":\"__className_f367f3 h-1080px w-1920px\",\"children\":[[\"$\",\"$7\",null,{\"fallback\":null,\"children\":[[\"$\",\"$L8\",null,{}],[\"$\",\"$L9\",null,{}]]}],[\"$\",\"$L5\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L6\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"title\",null,{\"children\":\"404: This page could not be found.\"}],[\"$\",\"div\",null,{\"style\":{\"fontFamily\":\"system-ui,\\\"Segoe UI\\\",Roboto,Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\"\",\"height\":\"100vh\",\"textAlign\":\"center\",\"display\":\"flex\",\"flexDirection\":\"column\",\"alignItems\":\"center\",\"justifyContent\":\"center\"},\"children\":[\"$\",\"div\",null,{\"children\":[[\"$\",\"style\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}\"}}],[\"$\",\"h1\",null,{\"className\":\"next-error-h1\",\"style\":{\"display\":\"inline-block\",\"margin\":\"0 20px 0 0\",\"padding\":\"0 23px 0 0\",\"fontSize\":24,\"fontWeight\":500,\"verticalAlign\":\"top\",\"lineHeight\":\"49px\"},\"children\":\"404\"}],[\"$\",\"div\",null,{\"style\":{\"display\":\"inline-block\"},\"children\":[\"$\",\"h2\",null,{\"style\":{\"fontSize\":14,\"fontWeight\":400,\"lineHeight\":\"49px\",\"margin\":0},\"children\":\"This page could not be found.\"}]}]]}]}]],\"notFoundStyles\":[]}]]}]}]],null],null],\"couldBeIntercepted\":false,\"initialHead\":[null,\"$La\"],\"globalErrorComponent\":\"$b\",\"missingSlots\":\"$Wc\"}]\n"])</script><script>self.__next_f.push([1,"a:[[\"$\",\"meta\",\"0\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}],[\"$\",\"meta\",\"1\",{\"charSet\":\"utf-8\"}],[\"$\",\"title\",\"2\",{\"children\":\"Unloxcyt Market Survey - Interactive Presentation\"}],[\"$\",\"meta\",\"3\",{\"name\":\"description\",\"content\":\"Comprehensive market analysis of Cosibelimab-ipdl for advanced cSCC\"}],[\"$\",\"meta\",\"4\",{\"name\":\"next-size-adjust\"}]]\n4:null\n"])</script></body></html>